Investigating how CES1 affects lung blood vessel health in pulmonary arterial hypertension
Official title: The Role of the CES1 in the Pathogenesis of Pulmonary Arterial Hypertension
Funded at Stanford University · NIH-11176379 · Data updated 2026-11-12
This study is looking at how a protein called CES1 affects the health of tiny blood vessels in the lungs, which could help us find new ways to treat pulmonary arterial hypertension (PAH) and improve the lives of people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 23, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $539,264 |
| NIH project number | 5R01HL172449-02 |
| Project ID | NIH-11176379 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those experiencing severe symptoms or unresponsive to current therapies.
✕Less likely to help
Patients with pulmonary arterial hypertension who have already responded well to existing treatments may not benefit from this research.
What this research studies
This research focuses on understanding the role of carboxylesterase 1 (CES1) in the development of pulmonary arterial hypertension (PAH), a serious condition that leads to high blood pressure in the lungs and heart failure. The study examines how CES1 influences the health of pulmonary microvascular endothelial cells (PMVECs), which are crucial for forming blood vessels. By exploring the metabolic processes and signaling pathways involved, the research aims to identify potential new therapeutic targets for improving patient outcomes. Patients with PAH may benefit from insights gained about CES1's role in their condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve blood vessel function and reduce the severity of pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in understanding metabolic pathways in PAH, suggesting that exploring CES1 could yield valuable insights.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: De Jesus Perez, Vinicio a — Stanford University
- Study coordinator: De Jesus Perez, Vinicio a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.